arginine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1549 74-79-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • l-arginine
  • L-Arg
  • arginine
  • arginine hydrochloride
  • arginine HCl
An essential amino acid that is physiologically active in the L-form.
  • Molecular weight: 174.20
  • Formula: C6H14N4O2
  • CLOGP: -3.04
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 5
  • TPSA: 125.22
  • ALOGS: -1.88
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.32 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.208 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.129 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.859 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.710 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 93.020 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 60.880 % High 1
herg hERG pIC50 5.502 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.183 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 8.054 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 89.160 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHUK,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K1,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 62
kinase-selectivity-class AXL,CAMK2D,CDK9,DDR1,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAP3K21,MAPK7,SIK2,STK33,TEK,TGFBR1 15
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.910 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.897 High 1
mppb Mouse plasma protein binding (% unbound) 93.560 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.168 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 88.090 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.194 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 85.450 % High 1
rppb Rat plasma protein binding (% unbound) 95.790 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 583.445 uM High 1

Approvals:

DateAgencyCompanyOrphan
June 23, 2021 PMDA FUJIFILM TOYAMA CHEMICAL Co., Ltd.
Feb. 28, 1973 FDA PHARMACIA AND UPJOHN
July 25, 2019 EMA Advanced Accelerator Applications

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemia 74.66 24.66 17 1080 6458 90620892
Foetal growth restriction 63.40 24.66 16 1081 9364 90617986
Hyperammonaemic crisis 57.72 24.66 7 1090 49 90627301
Infantile apnoea 41.98 24.66 8 1089 1279 90626071
Selective eating disorder 38.25 24.66 8 1089 2045 90625305
Cerebral haemorrhage 32.18 24.66 13 1084 34509 90592841
Ammonia increased 31.19 24.66 8 1089 4978 90622372
Right ventricular failure 27.89 24.66 10 1087 19195 90608155
Device related sepsis 26.63 24.66 7 1090 4786 90622564
Blood osmolarity decreased 25.35 24.66 5 1092 954 90626396

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematuria 80.06 24.77 37 1186 57762 42562350
Hyperammonaemic crisis 76.23 24.77 10 1213 53 42620059
Blindness cortical 55.64 24.77 10 1213 484 42619628

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 109.11 21.12 14 1919 108 110587258
Haematuria 78.16 21.12 35 1898 82970 110504396
Hyperammonaemia 68.80 21.12 20 1913 13712 110573654
Blindness cortical 52.27 21.12 10 1923 1125 110586241
Ammonia increased 41.24 21.12 12 1921 8238 110579128
Blood osmolarity decreased 26.72 21.12 6 1927 1472 110585894
Status epilepticus 25.54 21.12 12 1921 31559 110555807
Drug ineffective 22.91 21.12 68 1865 1520472 109066894
Right ventricular failure 21.41 21.12 10 1923 25944 110561422
Ureaplasma infection 21.14 21.12 5 1928 1541 110585825

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B05XB01 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Amino acids
ATC V03AF11 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:27027 micronutrient
CHEBI has role CHEBI:50733 nutraceutical
CHEBI has role CHEBI:59163 biomarker
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:78675 fundamental metabolite
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

B05XB Amino acids 2 drugs
alanyl glutaminelysine
V03AF Detoxifying agents for antineoplastic treatment 10 drugs
amifostinedexrazoxaneglucarpidaseleucovorinlevofolinic acidlysinemesnapaliferminrasburicasetrilaciclib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal radiation exposure from Lutetium (177Lu) oxodotreotide indication 218190002
Diagnostic Test for Growth Hormone Secretion indication
Renal tubular acidosis contraindication 1776003 DOID:14219
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Constipation contraindication 14760008 DOID:2089
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Metabolic acidosis contraindication 59455009
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hb SS disease contraindication 127040003 DOID:10923
Osteolysis contraindication 203522001
Myocardial infarction in recovery phase contraindication 418044006
Allergic Reactions contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.97 acidic
pKa2 11.72 Basic
pKa3 8.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Nitric oxide synthase, inducible Enzyme Kd 5.15 CHEMBL
G-protein coupled receptor family C group 6 member A GPCR AGONIST EC50 4.40 IUPHAR

External reference:

IDSource
4018668 VUID
N0000146979 NUI
D02982 KEGG_DRUG
1119-34-2 SECONDARY_CAS_RN
4018668 VANDF
4019067 VANDF
C0003765 UMLSCUI
CHEBI:29016 CHEBI
ARG PDB_CHEM_ID
CHEMBL1485 ChEMBL_ID
CHEMBL1200381 ChEMBL_ID
D001120 MESH_DESCRIPTOR_UI
DB00125 DRUGBANK_ID
1711 INN_ID
94ZLA3W45F UNII
6322 PUBCHEM_CID
DB17289 DRUGBANK_ID
1091 RXNORM
14778 MMSL
206 MMSL
399898 MMSL
40033 MMSL
4219 MMSL
7609 MMSL
7610 MMSL
d00578 MMSL
000926 NDDF
005095 NDDF
52625008 SNOMEDCT_US
63676001 SNOMEDCT_US
721 IUPHAR_LIGAND_ID
94ZLA3W45F INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
R-Gene HUMAN PRESCRIPTION DRUG LABEL 1 0009-0436 INJECTION, SOLUTION 10 g INTRAVENOUS NDA 17 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 1.20 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 690 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0202 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0206 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0210 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0214 INJECTION 920 mg INTRAVENOUS NDA 20 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 1.96 g INTRAVENOUS NDA 21 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 1.47 g INTRAVENOUS ANDA 18 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 1.15 g INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1101 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 489 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 489 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1123 INJECTION 575 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1125 INJECTION 575 mg INTRAVENOUS NDA 20 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1130 INJECTION, SOLUTION 1.20 g INTRAVENOUS ANDA 15 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1131 INJECTION, SOLUTION 0.73 g INTRAVENOUS ANDA 15 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1133 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1134 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1137 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1138 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1142 INJECTION 316 mg INTRAVENOUS NDA 20 sections